RhumbLine Advisers’s Palisade Bio PALI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$233K Buy
172,442
+11,669
+7% +$22.8K ﹤0.01% 3192
2026
Q2
$336K Buy
+160,773
New +$316K ﹤0.01% 2999
2015
Q2
– Hold
0
– -$104K – 3071
2015
Q1
– Hold
0
– – – 2949
2014
Q4
– Hold
0
– – – 2942
2014
Q3
– Hold
0
– – – 2887
2014
Q2
– Hold
0
– – – 2893

Other funds holding PALI

RhumbLine Advisers's PALI Position: Q3 2026 in Review

RhumbLine Advisers increased its Palisade Bio (PALI) stake by 7.3% in Q3 2026, buying an estimated $22.8K and bringing the position to 172,442 shares worth $233K. The position accounts for ﹤0.01% of the portfolio, ranked #3192.

RhumbLine Advisers first reported a position in PALI in Q2 2026 and has held it in 2 quarters since. The position peaked at $336K in Q2 2026. 114 funds tracked by Wall St. Rank hold PALI as of Q3 2026.

  • RhumbLine Advisers held 172,442 shares of Palisade Bio worth $233K as of Q3 2026.
  • RhumbLine Advisers bought 11,669 Palisade Bio shares in Q3 2026, an estimated $22.8K.
  • Palisade Bio made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #3192 holding.
  • RhumbLine Advisers first reported a position in Palisade Bio in Q2 2026 and has held it in 2 quarters since.
  • RhumbLine Advisers's Palisade Bio position peaked at $336K in Q2 2026.
  • 114 funds tracked by Wall St. Rank held Palisade Bio as of Q3 2026.

Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.